T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing
Published version of a preprint
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
T cell–retargeting therapies have transformed the therapeutic landscape for hematologic diseases. T cell–dependent bispecific antibodies (TDB) function as conditional agonists that induce a polyclonal T-cell response, resulting in target cell destruction and cytokine release. The relationship between this response and its effects on surrounding innate immune populations has not been fully explored. Here we show that treatment with mosunetuzumab in patients results in natural killer (NK) cell activation in the peripheral blood. We modeled this phenomenon in vitro and found that TDB-mediated killing activated NK cells, increasing NK function and antibody-dependent cellular cytotoxicity (ADCC), and enhanced the capability of macrophages to perform antibody-dependent cellular phagocytosis (ADCP). This enhancement was triggered by cytokines released through TDB treatment, with IL2 and IFNγ being major drivers for increased ADCC and ADCP, respectively. Surprisingly, cytolytic ability could be further augmented through neutralization of IL10 for NK cells and TNFα for macrophages. Finally, we showed that TDB treatment enhanced the efficacy of Fc-driven killing to an orthogonal solid tumor target in vivo. These results provide rationale for novel antibody therapy combinations that take advantage of both adaptive and innate immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Research works printed but not linked: 2
- Zahavi, 2018, Enhancing antibody-dependent cell-mediated cytotoxicity (ADCC): a strategy for improving antibody-based immunotherapy, Antib Ther, 1, 7
- Tripp, 1993, Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist, 3725
Cited by
Isshiki, Y., Chen, X., Teater, M. R., Karagiannidis, I., Nam, H. S., Cai, W., Meydan, C., Xia, M., Shen, H., Gutierrez, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.006 · Cited by 97
Mechanistic insights into resistance mechanisms to T cell engagers
Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A., & Bacac, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583044 · Cited by 42
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
CXCR6+ T cells are required for CD3xCD20 Bispecific Antibody Efficacy in B cell LymphomasPreprint
Berning, P., Fukasawa, K., Rahman, J., Melendez, L., Ketavarapu, M., Mitra, S., Chen, C.-Y., Horie, T., Ishigaki, Y., Douglas, M., et al. (2024) · medRxiv · doi:10.1101/2024.07.02.24309792 · Cited by 10
Marischen, L., Fritsch, J., Ilic, J., Wahl, L., Bertsch, T., Knop, S. T., & Bold, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031262 · Cited by 7
Metadata
- Authors
- Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., & Polson, A. G.
- Affiliations
- Genentech (US)
- 1Genentech Research and Early Development, Genentech Inc., South San Francisco, California.
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2023-10-27
- Volume
- 12
- Issue
- 1
- Pages
- 60-71
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W4388014101
- Cited by
- 13
- References
- 34
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mosunetuzumab, NK cell activation, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, macrophages, innate immune activation, interleukin-2, interferon-gamma, IL-10, TNF-α, cytokine production, solid tumors, hematologic disorders, antibody combination therapy
- MeSH terms
- Antibody-Dependent Cell Cytotoxicity, Humans, Immunity, Innate, T-Lymphocytes, Cytokines, Antibodies, Bispecific, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing. https://app.cochat.ai/papers/10.1158/2326-6066.cir-23-0072
- The paper
- Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., & Polson, A. G. (2024). T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-23-0072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.